[{"id":"ea774ee2-dd2b-414c-a96d-08591fa7b0fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02456571","created_at":"2021-01-18T11:47:06.434Z","updated_at":"2024-07-02T16:36:58.289Z","phase":"","brief_title":"CTC Immune Checkpoint","source_id_and_acronym":"NCT02456571","lead_sponsor":"Duke University","biomarkers":" PD-L1 • CD276 • PD-L2","pipe":" | ","alterations":" PD-L2 expression","tags":["PD-L1 • CD276 • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Xtandi (enzalutamide) • abiraterone acetate • Provenge (sipuleucel-T)"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 06/13/2019","primary_completion_date":" 06/13/2019","study_txt":" Completion: 06/13/2019","study_completion_date":" 06/13/2019","last_update_posted":"2019-07-09"}]